News about "ulcerative colitis "

Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study

Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.

Ulcerative Colitis | 18/02/2026 | By News Bureau |  142

Biocon Pharma Receives US FDA Nod for Tofacitinib Extended-Release Tablets

Biocon Pharma has received approval from the US Food and Drug Administration (US FDA) for its ANDA for tofacitinib extended-release tablets, securing final approval for the 11 mg strength and tentative approval for the 22 mg strength.

Ulcerative Colitis | 19/11/2025 | By Dineshwori |  252

Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis

Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.

Ulcerative Colitis | 28/10/2025 | By Dineshwori |  247

MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients

The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.

Ulcerative Colitis | 14/10/2025 | By Dineshwori |  451

Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases

Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.

Ulcerative Colitis | 07/10/2025 | By Dineshwori |  427

Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases

Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.

Ulcerative Colitis | 06/10/2025 | By Dineshwori |  226

Prometheus Laboratories Collaborates with Celltrion for Anser Testing

Prometheus is the first specialty lab to validate TDM testing for both intravenous and subcutaneous infliximab, supporting the growing demand for at-home treatment options.

Ulcerative Colitis | 28/08/2025 | By Dineshwori |  168

Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar

Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.

Ulcerative Colitis | 06/08/2025 | By Dineshwori |  268

Johnson & Johnson Gets US FDA Approval for TREMFYA

TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.

Ulcerative Colitis | 12/09/2024 | By Aishwarya |  437